Last reviewed 2026-05-14 · How we verify

FLOREDIL

Phase 2 active Small molecule

FLOREDIL is a floredil drug. It is currently in Phase 2 development.

FLOREDIL works by interacting with a specific biological target to produce a therapeutic effect.

FLOREDIL is a small molecule drug in the floredil class, but specific details about its development, ownership, and commercial status are not available. Its target and mechanism of action are also unknown. FLOREDIL is not FDA-approved, and its approved indications, half-life, bioavailability, and generic manufacturers are not specified. As a result, key safety considerations and commercial status cannot be determined. Further research is needed to understand FLOREDIL's properties and potential uses.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FLOREDIL
Drug class	floredil
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, the exact mechanism of FLOREDIL is not well understood, and more research is needed to determine how it produces its effects in the body. In general, small molecule drugs like FLOREDIL are designed to bind to specific proteins or receptors, altering their activity and leading to changes in cellular behavior. This can result in a range of therapeutic effects, depending on the specific target and the drug's properties.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FLOREDIL CI brief — competitive landscape report
FLOREDIL updates RSS · CI watch RSS

Frequently asked questions about FLOREDIL

What is FLOREDIL?

FLOREDIL is a floredil drug.

How does FLOREDIL work?

FLOREDIL works by interacting with a specific biological target to produce a therapeutic effect.

What drug class is FLOREDIL in?

FLOREDIL belongs to the floredil class. See all floredil drugs at /class/floredil.

What development phase is FLOREDIL in?

FLOREDIL is in Phase 2.

Drug class: All floredil drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing